|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Four of the five TCC lines expressed mutant p53.
|
14679155 |
2003 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the feasibility and activity of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma (TCC) of the urothelium and to relate the activity of this combination to the mutational status of p53.
|
10736495 |
2000 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
This prompted our investigation to explore the global Alu methylation and the promoter methylation of the novel putative tumor suppressor genes caveolin-1 and hDAB2IP, and of p53 in transitional cell carcinomas (TCC), squamous cell carcinomas and undifferentiated small cell carcinomas of the urinary bladder.
|
16328005 |
2006 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied whether p53 status has any predictive value on the outcome of intravesical adriamycin (ADR) instillation for superficial transitional cell carcinoma (TCC) of the bladder.
|
12926093 |
2003 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to evaluate the prognostic relevance of p53 expression in T1 TCC of the bladder.
|
10828662 |
2000 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As expected, none of eight TCCs with mutant p53 responded to gamma radiation by elevation of p53, p21(WAF1), or mdm2 or by cell cycle arrest.
|
10919661 |
2000 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the authors determined the prognostic significance of proliferating cell nuclear antigen (PCNA), p53 protein, and nm23 protein, as well as nuclear DNA content in specimens with TCC of the bladder.
|
8859190 |
1996 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
This approach could be useful in targeting apoptosis to TCC and other carcinomas lacking p53 and RB function.
|
12370752 |
2002 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Brenner tumors and TCCs differed mainly in the expression of EGFR, p16, and p53.
|
19033864 |
2009 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also, more polysomic TCCs were found in muscle-invasive than in superficial cases (P< 0.01 ), and there was a difference in both p53 overexpression or PCNA-LI between disomic and polysomic TCCs (P< 0.01).
|
9712438 |
1998 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyze the correlation between the genotypic and phenotypic patterns of p53 in patients with transitional cell carcinoma (TCC) of the urinary bladder.
|
18025850 |
2007 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of cases with p53 mutations within Arg72-containing allele was higher for advanced-stage TCCs (chi(2) = 5.320, P = 0.021) than for TCCs with those arising in Pro72-containing allele.
|
12006537 |
2002 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpressed p53 protein was statistically more common in invasive and non-papillary (p<0.05) and in high-grade TCCs (p<0.05).
|
9852285 |
1998 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the roles of p53 and bcl-2 as prognostic factors in TCC of bladder in patients younger than 40 years.
|
11464113 |
2001 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent investigations have demonstrated alterations of the p53 tumor-suppressor gene in a considerable number of transitional-cell carcinoma (TCC) specimens.
|
8087143 |
1994 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty-one of the tumours were p53 positive. p53 positive tumours were significantly more often found in TCC with low SPFs than in those with high SPFs.
|
8102536 |
1993 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A direct statistically significant association was detected between c-erb-B2 expression and Bcl-2 and p53 expression in TCC and SCC specimens.
|
26653553 |
2015 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have used microdissection of paraffin-embedded histological sections and polymerase chain reaction (PCR)-based direct DNA sequencing for 54 transitional cell carcinoma (TCC) of the bladder, to examine critically the association between TP53 nuclear accumulation determined by immunohistochemistry and the presence of TP53 mutations, and to examine their relationship to tumour stage and grade, as well as patient survival.
|
9649138 |
1998 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
LOH on 17p, where the TP53 gene is located, was more common in Egyptian TCC than in SCC.
|
10048962 |
1999 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings support suggestions that (i) inactivation of p53 and/or pRb constitutes a causal step in the etiology of invasive TCC, (ii) papillary and invasive TCC may have different molecular causes, and (iii) carcinoma in situ can represent an early stage in the progression to invasive TCC.
|
10980120 |
2000 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we concluded that dysfunction of p53 plays a major role in the development of TCCs of bladder in Korean patients.
|
7483675 |
1995 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a rapid technique for detection of LOH in the p53 gene of patients with transitional cell carcinoma (TCC) of the bladder.
|
10688045 |
2000 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high-grade dysplasia/CIS group (n = 16) had a similar high percentage and intensity of p53 staining (45.3 +/- 4.3%; 28.2 +/- 6.1 arbitrary units [AU]) as the TCC group (n = 16.
|
12607601 |
2002 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression pattern of PAX5 in the tissue of superficial bladder transitional cell carcinoma (TCC), its prognostic value and its correlation with p53 immunohistochemistry and p53 mutation analysis were evaluated.
|
14577491 |
2002 |
|
TARSAL-CARPAL COALITION SYNDROME
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The best documented factors involved in urinary bladder transitional cell carcinoma (TCC) are ras proto-oncogene activation and p53 suppressor gene mutations.
|
10079253 |
1999 |